Biotech & Pharma

PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models

30 sec read0 views0 listens

A preclinical study shows that combining HER3-DXd with the PARP inhibitor olaparib intensifies DNA damage in tumor cells and boosts antitumor immune activity, potentially overcoming drug resistance in non-small cell lung cancer (NSCLC). This combination therapy could be effective across various genetic forms of NSCLC and may have broader applications in other solid tumors. Developers should monitor further clinical trials to assess the safety and efficacy of this approach in human patients.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Real Estate & Home8 hours ago27 sec read

Developer Graya wins approval for luxury St Lucia 'Silk' project on prime Brisbane riverfront

Local developer Graya has secured approval to build a 25-level luxury residential tower called Silk in St Lucia, Brisbane. This development targets downsizing homeowners and includes exclusive split-floor and full-floor apartments with riverfront vie...

Ali Nemati

Health & Medicine14 hours ago32 sec read

STAT+: Pharmalittle: We're reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more

President Trump's initiative to make GLP-1 weight loss drugs accessible through Medicaid for low-income Americans is faltering, with only Indiana participating and other states either ending or considering ending coverage due to budget constraints. A...

Ali Nemati

Real Estate & Home16 hours ago22 sec read

JLL: Planning approved for West Lothian industrial and logistics scheme and Major Industrial Deal Completed in Scotland's Central Belt

West Lothian Council has granted planning permission for a 55,500 sq m industrial and logistics development at Arches Business Park in Broxburn. This approval is crucial as it addresses the shortage of modern, high-quality space needed by businesses ...

Ali Nemati